Most investors don’t understand the threat that prostate cancer poses to them. And the numbers that are affected each year.
If all investors knew that a simple blood test, once a year, would identify the threat and direct them to screening and (CU6) diagnostic imaging, they’d be buying the stock, imv.
Ann: Clarity to present at ASCO and SNMMI 2023 Annual Meetings, page-3
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.67 |
Change
-0.230(3.33%) |
Mkt cap ! $2.103B | |||
| Open | High | Low | Value | Volume |
| $6.85 | $6.91 | $6.65 | $6.534M | 965.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 12427 | $6.67 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.68 | 38 | 2 |
View Market Depth
| Last trade - 16.10pm 29/08/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |